Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab

Thomas Elmer Witzig, David J. Inwards, Thomas Matthew Habermann, Ahmet Dogan, Paul J. Kurtin, John B. Gross, Anuradha Ananthamurthy, Kay M. Ristow, James A. Garrity

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

OBJECTIVE: To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab. PATIENTS AND METHODS: Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab. RESULTS: Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m2, intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab. CONCLUSION: Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.

Original languageEnglish (US)
Pages (from-to)692-699
Number of pages8
JournalMayo Clinic Proceedings
Volume82
Issue number6
DOIs
StatePublished - 2007

Fingerprint

Pseudolymphoma
Anti-Idiotypic Antibodies
Monoclonal Antibodies
Therapeutics
Biopsy
Rituximab
Non-Hodgkin's Lymphoma
B-Lymphocytes
Maintenance
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab. / Witzig, Thomas Elmer; Inwards, David J.; Habermann, Thomas Matthew; Dogan, Ahmet; Kurtin, Paul J.; Gross, John B.; Ananthamurthy, Anuradha; Ristow, Kay M.; Garrity, James A.

In: Mayo Clinic Proceedings, Vol. 82, No. 6, 2007, p. 692-699.

Research output: Contribution to journalArticle

Witzig, TE, Inwards, DJ, Habermann, TM, Dogan, A, Kurtin, PJ, Gross, JB, Ananthamurthy, A, Ristow, KM & Garrity, JA 2007, 'Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab', Mayo Clinic Proceedings, vol. 82, no. 6, pp. 692-699. https://doi.org/10.4065/82.6.692
Witzig, Thomas Elmer ; Inwards, David J. ; Habermann, Thomas Matthew ; Dogan, Ahmet ; Kurtin, Paul J. ; Gross, John B. ; Ananthamurthy, Anuradha ; Ristow, Kay M. ; Garrity, James A. / Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab. In: Mayo Clinic Proceedings. 2007 ; Vol. 82, No. 6. pp. 692-699.
@article{f8fd63096e0240d7be55a32e840ab632,
title = "Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab",
abstract = "OBJECTIVE: To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab. PATIENTS AND METHODS: Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab. RESULTS: Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73{\%}); the other 26 (27{\%}) had a pseudolymphoma. Eleven (42{\%}) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m2, intravenously each week for 4 doses, and 10 (91{\%}) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab. CONCLUSION: Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.",
author = "Witzig, {Thomas Elmer} and Inwards, {David J.} and Habermann, {Thomas Matthew} and Ahmet Dogan and Kurtin, {Paul J.} and Gross, {John B.} and Anuradha Ananthamurthy and Ristow, {Kay M.} and Garrity, {James A.}",
year = "2007",
doi = "10.4065/82.6.692",
language = "English (US)",
volume = "82",
pages = "692--699",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab

AU - Witzig, Thomas Elmer

AU - Inwards, David J.

AU - Habermann, Thomas Matthew

AU - Dogan, Ahmet

AU - Kurtin, Paul J.

AU - Gross, John B.

AU - Ananthamurthy, Anuradha

AU - Ristow, Kay M.

AU - Garrity, James A.

PY - 2007

Y1 - 2007

N2 - OBJECTIVE: To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab. PATIENTS AND METHODS: Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab. RESULTS: Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m2, intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab. CONCLUSION: Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.

AB - OBJECTIVE: To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab. PATIENTS AND METHODS: Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab. RESULTS: Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m2, intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab. CONCLUSION: Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.

UR - http://www.scopus.com/inward/record.url?scp=34249936959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249936959&partnerID=8YFLogxK

U2 - 10.4065/82.6.692

DO - 10.4065/82.6.692

M3 - Article

VL - 82

SP - 692

EP - 699

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -